ArticleESMO gastrointestinal oncology2026
Comparative outcomes with low-dose and standard-dose immune checkpoint inhibitors in microsatellite stable advanced gastric/gastroesophageal adenocarcinoma.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The combination of chemotherapy and immune checkpoint inhibitors (ICIs) is usually considered standard in advanced gastric/gastroesophageal adenocarcinoma (GC) with combined positive score (CPS) 6≥5. Methods: Data of patients with microsatellite stable advanced GCs receiving chemotherapy combined with ICIs between August 2021 and February 2024 were collated from eight institutions in India. The primary endpoint was to compare median overall survival between patients receiving standard-dose ICIs (SD-ICIs) and low-dose ICIs (LD-ICIs) as first-line treatment when CPS ≥5. Results: Data of 288 patients were collated, of whom 256 patients had adequate data for analysis. A CPS ≥5 was seen in 161 patients (63%). Nivolumab was used in a majority of patients (75%). After propensity matching for age, 124 patients (62 patients receiving LD-ICIs and SD-ICIs, each) were available for analysis. With a median follow-up of 9.8 months [95% confidence interval (CI) 7.6-12.1 months], there was no difference in median overall survival between patients receiving LD-ICIs and SD-ICIs (16.8 months, 95% CI 7.59-25.97 months versus 16.1 months, 95% CI 10.3 months-not reached, Conclusions: LD-ICIs can be evaluated in combination with chemotherapy in patients with advanced GC and CPS ≥5 where standard dosing is not feasible, pending evidence from prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.